The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 07, 2017
Filed:
Mar. 13, 2014
Applicant:
Seragon Pharmaceuticals, Inc., San Diego, CA (US);
Inventors:
Nicholas D. Smith, San Diego, CA (US);
Steven P. Govek, San Diego, CA (US);
Mehmet Kahraman, La Jolla, CA (US);
Celine Bonnefous, San Diego, CA (US);
Jackaline D. Julien, Del Mar, CA (US);
Assignee:
GENENTECH, INC., South San Francisco, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/415 (2006.01); C07D 231/12 (2006.01); C07D 277/22 (2006.01); A61K 31/426 (2006.01); C07D 417/04 (2006.01); C07D 277/30 (2006.01); C07D 295/155 (2006.01); C07D 213/55 (2006.01); C07D 275/02 (2006.01); C07D 233/60 (2006.01); C07D 263/32 (2006.01); C07D 261/08 (2006.01); C07D 417/10 (2006.01); C07D 401/10 (2006.01); C07D 257/04 (2006.01); C07D 403/12 (2006.01); C07D 211/14 (2006.01); C07D 409/10 (2006.01);
U.S. Cl.
CPC ...
C07D 417/04 (2013.01); C07D 211/14 (2013.01); C07D 213/55 (2013.01); C07D 231/12 (2013.01); C07D 233/60 (2013.01); C07D 257/04 (2013.01); C07D 261/08 (2013.01); C07D 263/32 (2013.01); C07D 275/02 (2013.01); C07D 277/30 (2013.01); C07D 295/155 (2013.01); C07D 401/10 (2013.01); C07D 403/12 (2013.01); C07D 409/10 (2013.01); C07D 417/10 (2013.01);
Abstract
Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.